Italia markets closed

Valneva SE (0OB3.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
15,66-0,88 (-5,32%)
Alla chiusura: 06:29PM GMT
Schermo intero
Chiusura precedente16,54
Aperto16,01
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno15,43 - 16,27
Intervallo di 52 settimane15,43 - 16,27
Volume273.022
Media VolumeN/D
Capitalizzazione1,405B
Beta (5 anni mensile)0,65
Rapporto PE (ttm)N/D
EPS (ttm)-1,35
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant

    Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant (B.1.1.529 lineage) 100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant Saint Herblain (France), January 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laborat

  • GlobeNewswire

    VALNEVA Declaration of shares and voting rights - December 31, 2021

    VALNEVA Declaration of shares and voting rights December 31, 2021 __________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 6, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this chang

  • GlobeNewswire

    Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001

    Saint Herblain (France), January 6, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. As announced in December 20211, the Company commenced rolling submissions for initial approval of VLA2001 with the European Medicines Agency, the UK MHRA and the Bahraini NHRA, and is continuing to work close